Jazz Pharmaceuticals Receives a Hold from H.C. Wainwright

H.C. Wainwright analyst Oren Livnat reiterated a Hold rating on Jazz Pharmaceuticals (NASDAQ: JAZZ) today and set a price target of $160. The company’s shares opened today at $152.

According to TipRanks.com, Livnat has currently no stars on a ranking scale of 0-5 stars, with an average return of -10.5% and a 29.4% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Pacira Pharmaceuticals, and Agile Therapeutics.

Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $189.22.

See today’s analyst top recommended stocks >>

The company has a one-year high of $162.59 and a one-year low of $128.58. Currently, Jazz Pharmaceuticals has an average volume of 404.3K.

Based on the recent corporate insider activity of 85 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry.